Navigation Links
Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income
Date:11/21/2008

LARGO, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter ended September 30, 2008 (FY2009).

Net sales, excluding royalty income, increased 5.3% to $1,761,526 in FY2009 first quarter, compared with $1,673,361 in the previous year first quarter (FY2008). The increase was primarily a result of continued growth of the Company's C-Vue brand of specialty contact lenses, sold exclusively to licensed eye care professionals.

FY2009 first quarter net income increased 23.6% to a record first quarter of $466,367, or $.10 per diluted share, compared with $377,296 or $0.08 per diluted share in the previous year quarter.

Royalty income for the FY2009 first quarter increased 16.4% to a record first quarter of $713,397 compared with $612,799 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to increase, resulting in continued double-digit royalty income growth.

FY2009 first quarter income before taxes increased 24.6% to a record first quarter $768,259 compared with $616,501 in the prior-year quarter. After recording net income tax expense of $301,892, Unilens reported net income of $466,367 for the quarter, or $0.10 per diluted share. In the FY2008 first quarter, the Company reported net income of $377,296, or $0.08 per diluted share, which included income tax expense of $239,205.

"We are pleased to report record first quarter sales, royalties and income for our FY2009 first quarter," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Strong double-digit growth for our C-Vue brand of lenses sold exclusively to independent practitioners, combined with a 16% growth in royalty revenue derived from Bausch & Lomb's sales of multifocal lenses that use our key technologies, was responsible for this outstanding performance."

"I am also pleased to report that the Unilens' Board of Directors declared its regular quarterly dividend of US $0.09 per common share, payable next Friday November 28, 2008. "This decision was based on the Company's strong balance sheet, and projected operating cash flows and is consistent with the Board's commitment that shareholders should share directly in the earnings achieved by management while continuing to execute our growth strategy," concluded Mr. Pecora.

About Unilens Vision Inc. - "The Independent Eye Care Professionals Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue(R) brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

    For more information, please contact:
    Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531



                              UNILENS VISION INC.
                         FIRST QUARTER - FISCAL 2009
                CONDENSED CONSOLIDATED FINANCIAL INFORMATION

    (All figures in U.S. Dollars)
    RESULTS OF OPERATIONS
                                                  Three Months   Three Months
                                                     Ended          Ended
                                                 Sept. 30, 2008 Sept. 30, 2007

       Sales                                       $1,761,526     $1,673,361
       Cost of sales                                  935,132        904,397
                                                      826,394        768,964
       Expenses                                       771,961        754,952
       Income from operations                          54,433         14,012
       Other items:
       Royalty income                                 713,397        612,799
       Other income (expense)                           2,585        (27,141)
       Remeasurement (loss) income                     (4,427)         2,541
       Interest income                                  2,271         14,290
                                                      713,826        602,489
       Income before income tax                       768,259        616,501
       Income tax expense                             301,892        239,205
       Net income for the period                     $466,367       $377,296
       Net income per common share:
         Basic                                          $0.10          $0.08
         Diluted                                        $0.10          $0.08
    CASH FLOWS
    Provided (used) by:
       Operating activities                          $706,683       $689,258
       Investing activities                           (32,600)       (28,123)
       Financing activities                        (1,774,779)    (1,744,008)
       Decrease in cash                           $(1,100,696)   $(1,082,873)


    BALANCE SHEET
                                                  Sept. 30, 2008 June 30, 2008
       Cash                                          $498,353     $1,603,476
       Total assets                                 5,432,149      6,784,128
       Current liabilities                            913,867        957,434
       Total liabilities                              913,867        957,434
       Stockholders' equity                        $4,518,282     $5,826,694

'/>"/>
SOURCE Unilens Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens
2. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
3. Unilens Vision Announces New Policies Aimed at Increasing Eye Care Professionals Profitability
4. Unilens Vision Reports Increased Royalty Income
5. Unilens Launches Aspheric C-VUE(R) Daily Disposable Lens
6. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
7. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
8. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
9. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
10. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
11. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... surgery as possible. With this in mind, SIGVARIS has created a new line ... clot) during bed rest and provide the benefits of graduated compression when transitioning ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance ... in Hamilton County, is embarking on a charity drive with the aim of ... homes for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... travel vaccines market to grow at a CAGR of 6.83% during ... and the growth prospects of the global travel vaccines market for ... generated from the sales of various vaccines administered to actively immunize ...
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
Breaking Medicine Technology: